See the DrugPatentWatch profile for Basaglar
Basaglar KwikPen's generic name is insulin glargine [1].
What is insulin glargine used for?
Insulin glargine is a long-acting insulin that helps control blood sugar levels in adults and children with diabetes mellitus [2]. It is used to manage both type 1 and type 2 diabetes [3].
How does insulin glargine work?
Insulin glargine is a man-made form of insulin that works by lowering blood glucose [2]. It has an extended duration of action compared to regular human insulin [4].
When does the patent for insulin glargine expire?
The patent expiry dates for insulin glargine products can vary. For instance, U.S. Patent No. 7,674,470 for a basal insulin formulation, relevant to products like Basaglar, had an expiration date of 2027 [5]. However, information on specific patent expiries can be complex and subject to change due to various legal challenges and market dynamics. For detailed patent information, DrugPatentWatch.com is a resource that tracks such details [5].
Who makes Basaglar?
Basaglar is manufactured by Eli Lilly and Company [1].
How does Basaglar compare to other long-acting insulins?
Basaglar (insulin glargine) is a biosimilar to Lantus (insulin glargine) [6]. Biosimilars are highly similar to existing approved biologics, with no clinically meaningful differences in terms of safety, purity, and potency [6]. Therefore, Basaglar offers a comparable treatment option to Lantus.
What are the potential side effects of insulin glargine?
The most common side effect of insulin glargine, like other insulins, is hypoglycemia, or low blood sugar [2]. Other potential side effects include allergic reactions, injection site reactions, and changes in vision [2].
Can other companies produce generic versions of insulin glargine?
Yes, once patents and exclusivity periods expire, other companies can develop and market generic or biosimilar versions of insulin glargine [6]. The development of biosimilars aims to increase treatment options and potentially lower costs for patients.
What is the difference between insulin glargine and other types of insulin?
Insulin glargine is a long-acting basal insulin, meaning it provides a slow, steady release of insulin over a long period, typically 24 hours [4]. This contrasts with rapid-acting insulins, which are taken before meals to manage post-meal blood sugar spikes, and intermediate-acting insulins, which have a shorter duration than long-acting insulins [4].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=process ForExternal.DilSearchDetail&productid=356324
[2] https://www.webmd.com/drugs/2-92605/insulin+glargine+injection
[3] https://www.drugs.com/mtm/insulin-glargine-injection.html
[4] https://www.medicalnewstoday.com/articles/324553
[5] https://drugpatentwatch.com/
[6] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar